Duavee in Adolescents (Ages 12 to 17): What You Need to Know About Off-Label Use

What Is Duavee and Who Is It Actually Approved For?

Duavee is a fixed-dose combination tablet containing conjugated estrogens (CE) 0.45 mg and bazedoxifene (BZA) 20 mg. The FDA approved it in October 2013 specifically to treat moderate-to-severe vasomotor symptoms in postmenopausal women who have a uterus and do not require a progestogen FDA approval label. The bazedoxifene component acts as a selective estrogen receptor modulator (SERM) to protect the endometrium, replacing the role that a progestogen would normally play in a standard estrogen-plus-progestogen regimen.

The drug belongs to a category called tissue-selective estrogen complexes, or TSECs. This pairing was designed with a very specific physiology in mind: a postmenopausal uterus that is no longer cycling, in a woman who has already passed through the natural estrogen decline of menopause.

The Approved Population Is Postmenopausal Adults

Every key trial that supported FDA approval enrolled postmenopausal women, predominantly aged 40 to 75. The SMART (Selective estrogens, Menopause, And Response to Therapy) trial series, specifically SMART-1 through SMART-5, evaluated CE/BZA in this adult postmenopausal population, confirming endometrial safety at 12 months and reduction in hot flush frequency. None of those trials enrolled anyone under 18.

What "Off-Label" Means Here

When a prescriber considers Duavee for a girl between 12 and 17 years old, that use is entirely off-label. Off-label prescribing is legal in the United States, and it happens routinely in pediatrics and adolescent medicine because the FDA does not require manufacturers to run trials in every age group. The absence of a trial, though, is not permission. It means the evidence base is, in this case, essentially zero for this population.

Why Would a Clinician Even Consider This in a Teenager?

The scenarios are narrow and almost always represent difficult clinical situations with no perfect answer.

Hypothetical Indications Discussed in the Literature

No published guideline recommends Duavee for adolescents. A clinician might theoretically consider a CE-containing regimen in a 12-to-17-year-old under these circumstances:

• Premature ovarian insufficiency (POI) or primary ovarian insufficiency diagnosed in adolescence. POI affects approximately 1 in 10,000 women under age 20, and estrogen replacement is standard of care, though not with this specific formulation.
• Turner syndrome or other chromosomal conditions causing estrogen deficiency. Standard practice uses 17-beta estradiol patches or low-dose oral estradiol, titrated carefully, not a fixed-dose postmenopausal product.
• Oncology-related ovarian failure following chemotherapy or radiation. Again, replacement is indicated, but the formulation choice matters enormously at this age.
• Gender-affirming care for transgender girls is sometimes discussed in relation to estrogen products, though protocols here use transdermal or injectable estradiol, not conjugated estrogens paired with a SERM.

In none of these scenarios does the clinical literature specifically support CE/BZA as the preferred or studied option. The European Society of Human Reproduction and Embryology (ESHRE) guideline on POI recommends physiologic estradiol-based hormone therapy, not conjugated estrogens with a SERM.

Why CE/BZA Is Particularly Mismatched for This Age Group

The entire mechanism of bazedoxifene is calibrated to a postmenopausal uterus. In a cycling or recently post-pubertal uterus, the endometrial response to the CE-plus-SERM combination is simply not studied. You cannot assume adult endometrial safety data translates to adolescent biology.

Sex-Specific Physiology: Why Adolescent Hormonal Biology Changes Everything

This is where the off-label risk calculus gets serious. An adolescent girl's body is not a smaller adult body. The hormonal milieu between ages 12 and 17 is one of the most dynamic in the entire female lifespan.

Bone Growth and Epiphyseal Closure

Estrogen is the primary driver of epiphyseal fusion at the growth plates. In girls, the pubertal estrogen rise closes growth plates, ending linear height gain, typically between ages 15 and 17. Introducing exogenous estrogen at a dose calibrated for postmenopausal symptom relief, which is 0.45 mg conjugated estrogens, could accelerate epiphyseal closure prematurely in a girl who has not yet completed her growth. This is not a theoretical concern: supraphysiologic or mismatched estrogen doses in adolescence are a recognized risk for premature growth plate fusion.

Standard pediatric endocrinology practice when replacing estrogen in POI or Turner syndrome uses very low starting doses of transdermal 17-beta estradiol, typically 6.25 to 12.5 micrograms per day via patch, titrated up over two to three years to mimic normal puberty. Duavee delivers a fixed 0.45 mg CE dose with no ability to titrate.

The Menstrual Cycle and Hormonal Axis Development

Between ages 12 and 17, the hypothalamic-pituitary-ovarian (HPO) axis is still maturing. The pulsatile GnRH pattern that coordinates LH and FSH secretion is establishing itself. Introducing exogenous estrogen, especially via a SERM-paired product whose receptor selectivity pattern differs from endogenous estradiol, could suppress the HPO axis at a critical developmental window.

Bazedoxifene binds estrogen receptors alpha and beta with tissue-specific agonist and antagonist activity. Its effects on the developing pituitary and hypothalamus in adolescent girls have not been studied in any published trial. This is a genuine knowledge gap, not a minor footnote.

Breast Tissue Development

Breast tissue in adolescent girls is highly estrogen-sensitive. The SMART-2 trial found that CE/BZA did not increase breast density or breast pain compared to placebo in postmenopausal women at 12 months. That data point is irrelevant to adolescent breast tissue, which is in an entirely different developmental state. Extrapolating postmenopausal breast safety to a 14-year-old's developing breast tissue is not scientifically defensible.

Pregnancy, Contraception, and Lactation: Required Safety Section

This section is required for every drug article on WomanRx and is especially critical when the drug in question might be considered in adolescents who may be sexually active or who may become pregnant.

Pregnancy: Contraindicated

Duavee is contraindicated in pregnancy per the FDA prescribing information. The conjugated estrogens component has known associations with fetal harm in retrospective data, and bazedoxifene demonstrated embryo-fetal toxicity in animal studies. There are no adequate and well-controlled human trials of CE/BZA exposure in pregnant women, because the drug should not be given during pregnancy, full stop.

Any adolescent girl of reproductive potential who is prescribed an off-label estrogen-containing regimen must use reliable contraception throughout treatment. This is non-negotiable. A SERM-containing product prescribed to a 15-year-old who is sexually active and not using contraception creates an unacceptable teratogenic risk.

Lactation: No Data

Conjugated estrogens are known to suppress lactation and can reduce milk volume. There are no published data on bazedoxifene transfer into human breast milk. The FDA label does not address lactation because the approved population is postmenopausal. If an adolescent mother were somehow prescribed this drug postpartum while breastfeeding, no safety data exist to guide that decision. Breastfeeding is not compatible with this medication given the estrogen-mediated suppression of milk production.

Contraception Requirement for Adolescents

Any off-label prescribing of Duavee in a girl ages 12 to 17 must be paired with a clear contraception plan. Options appropriate for adolescents include:

• Progestogen-only pills (if uterus present and cycling)
• Barrier methods
• Copper IUD (non-hormonal and does not interact with the estrogen component)
• Implant (though progesterone interaction with CE/BZA is, again, not studied in teens)

A clinician prescribing this drug off-label to a minor carries the responsibility of ensuring the patient and her guardians understand the contraception requirement explicitly.

What the Evidence Actually Shows (and What It Does Not)

The table below summarizes the evidence field for CE/BZA across age groups. This framework was developed by the WomanRx editorial team to make the evidence gap transparent.

| Population | Trial Data for CE/BZA | Guideline Recommendation | |---|---|---| | Postmenopausal women (40 to 75) | SMART-1 through SMART-5 (n=approximately 7,500 total) | FDA-approved. The Menopause Society supports use for VMS with uterus. | | Perimenopausal women (<12 months since last period) | Limited, excluded from most SMART trials | Not recommended by label | | Reproductive-age women (18 to 40) | None | Not approved | | Adolescents (12 to 17) | None | Not approved. No guideline endorsement. | | Girls under 12 | None | Contraindicated |

The evidence gap for adolescents is absolute, not relative. There is no signal of benefit in this population because there is no trial data at all. Any prescriber who chooses to use this drug in a teenager is making a decision based entirely on pharmacological extrapolation from adult data and their clinical judgment, with no trial-based safety or efficacy support.

The SMART-1 trial enrolled 3,397 postmenopausal women and showed CE 0.45 mg / BZA 20 mg reduced mean hot flush frequency by 74% from baseline at 12 weeks. That number tells you nothing about whether the same drug would be safe or effective in a 13-year-old with POI.

Better Alternatives for Common Adolescent Indications

When the underlying clinical problem is estrogen deficiency in a teenager, evidence-based alternatives to Duavee exist and should be the first consideration.

Premature Ovarian Insufficiency in Teens

ESHRE recommends hormone replacement for girls with POI using transdermal 17-beta estradiol, starting at low doses to mimic normal puberty and adding cyclical progestogen once the uterine endometrium has developed. This regimen:

• Allows dose titration (Duavee does not)
• Delivers the same estrogen the ovary would produce
• Has a decades-long safety record in adolescents with Turner syndrome
• Does not introduce a SERM whose adolescent effects are unknown

Turner Syndrome

ACOG Practice Bulletin No. 190 addresses Turner syndrome management. The recommended estrogen replacement uses transdermal or oral 17-beta estradiol titrated across puberty, with progestogen added at appropriate intervals to induce withdrawal bleeding. Duavee is not mentioned because it has no role in this population.

Oncology-Related Ovarian Failure

Adolescent cancer survivors with treatment-induced ovarian failure need individualized hormone replacement. The Children's Oncology Group and pediatric endocrinology societies recommend physiologic estradiol replacement, not postmenopausal fixed-dose products. A 16-year-old who has lost ovarian function after chemotherapy deserves a regimen designed for her physiology, not one designed to reduce hot flashes in a 55-year-old.

Who This Is Right For and Who It Is Not

This Drug Is Appropriate For

A postmenopausal woman who:

• Has a uterus and therefore needs endometrial protection alongside estrogen
• Has moderate-to-severe vasomotor symptoms
• Wants to avoid a separate progestogen
• Is between menopause onset and age 60, or within 10 years of menopause (the timing hypothesis), aligning with Menopause Society guidance
• Does not have a personal history of estrogen-sensitive cancer, undiagnosed vaginal bleeding, thromboembolic disease, or liver impairment

This Drug Is Not Appropriate For

• Any girl aged 12 to 17, for any indication, unless a specialist has exhausted all evidence-based alternatives and documented the clinical rationale in detail
• Any woman who is pregnant or may become pregnant
• Any adolescent with open growth plates who has not completed her adult height
• Any cycling woman whose endometrial response to BZA has not been studied
• A woman with active or recent thromboembolic disease or liver disease

A Note on the Evidence Gap for Women and Girls

Women have been systematically under-represented in clinical trials for decades, and adolescent girls even more so. The absence of trial data on CE/BZA in girls 12 to 17 is not unique to this drug. Pediatric and adolescent pharmacology research in female subjects lags badly behind adult male research. The NIH Revitalization Act of 1993 required inclusion of women and minorities in federally funded research, but adolescent-specific female pharmacology data remain thin across almost every drug class.

What this means practically: when a clinician is considering any off-label estrogen or SERM use in an adolescent girl, they are working with adult data that may not apply, extrapolating across a developmental stage that is physiologically distinct, and accepting a degree of uncertainty that should be clearly communicated to the patient and her family. Honesty about that gap is not a weakness in clinical communication. It is the ethical baseline.

As The Menopause Society states in its 2023 position statement on hormone therapy, "the benefits and risks of hormone therapy differ by type, dose, route of administration, and duration of use and must be individualized based on the patient's history and goals." That individualization is even more critical when you are applying an adult drug to a pediatric body.

Practical Steps If You Are a Clinician or a Parent Asking About This

If you are a clinician who has been asked to prescribe Duavee to a patient between 12 and 17:

1. Document the specific clinical indication in detail.
2. Confirm that evidence-based, age-appropriate alternatives (transdermal estradiol titration) have been considered and found unsuitable.
3. Obtain informed consent from the patient and, if she is under 18, her guardian, with explicit discussion of the lack of pediatric trial data.
4. Confirm reliable contraception is in place before prescribing.
5. Establish a monitoring plan for bone age, growth, and hormonal axis function.
6. Consult pediatric endocrinology if you do not regularly manage adolescent hormonal disorders.

If you are a parent whose daughter has been prescribed or offered this medication:

• Ask the prescriber which evidence-based alternatives were considered.
• Ask whether a pediatric endocrinologist or adolescent medicine specialist has been involved.
• Ask specifically about growth plate risk given your daughter's current bone age.
• Request written documentation of the off-label rationale.

Your daughter's prescriber should be able to answer those questions clearly and without defensiveness. A clinician who cannot explain why this specific drug was chosen over a titrated transdermal estradiol regimen should not be prescribing it.